Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq -- Ignore unavailable to you. Want to Upgrade?

To: mlrb2113 who wrote (284)	7/2/2007 8:36:00 PM
From: Clarksterh	Read Replies (1) \| Respond to of 332

are there refined tests that can detect small changes in liver function/damage or other effects that would give a clue as to possible toxicity from higher dosages? It is possible (even probable) that the lower doses will show a lower rate of ALT>3xULN. But it isn't clear how the FDA would treat that - since the mapping of rate of elevated ALT to liver failure is not anywhere as clear as Hy's Law - e.g. moderate levels of statins have an incontrovertible excess rate of elevated ALT and yet do not have a liver failure problem.